Patents by Inventor Jacqueline Mary WURST

Jacqueline Mary WURST has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12227538
    Abstract: Provided herein are compounds that are glucocorticoid receptor agonists useful for the treatment of autoimmune and inflammatory diseases, processes for preparing these compounds, and pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: February 18, 2025
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Jacqueline Mary Wurst, James Andrew Jamison
  • Patent number: 12162905
    Abstract: The present invention provides a compound of Formula I: wherein R1 is H, halogen, C1-C3 alkyl, or C1-C3 alkoxy; R2 is H or halogen; and X is O, OCH2, or CH2, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis, rheumatoid arthritis, and lupus nephritis.
    Type: Grant
    Filed: February 28, 2023
    Date of Patent: December 10, 2024
    Assignee: Eli Lilly and Company
    Inventors: Ryan Edward Stites, Jacqueline Mary Wurst
  • Publication number: 20240173425
    Abstract: The present disclosure provides human CD33 antibodies and antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of myeloid cell associated diseases.
    Type: Application
    Filed: June 21, 2023
    Publication date: May 30, 2024
    Applicant: Eli Lilly and Company
    Inventors: Forest Hoyt Andrews, Joshua Ryan Clayton, Ross Edward Fellows, Bo Ma, Ying Tang, Jacqueline Mary Wurst, Pia Pauliina Yachi, Chiao-Wen Yang
  • Publication number: 20240018182
    Abstract: The present invention provides a compound of Formula I: wherein R is H or R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3, R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3 is NH2, or CH2NH2; and X is O, OCH2, OCH2CH2, OCH(CH3), CH2O, SCH2, CH2S, CH2, NHCH2, CH2NH, N(CH3)CH2, CH2CH2, C?C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.
    Type: Application
    Filed: September 8, 2023
    Publication date: January 18, 2024
    Inventors: Adel Ahmed Rashad AHMED, Joshua Ryan CLAYTON, Jose Eduardo LOPEZ, William Thomas MCMILLEN, Ryan Edward STITES, Takako WILSON, Jacqueline Mary WURST
  • Patent number: 11787834
    Abstract: The present invention provides a compound of Formula I: wherein R is H or R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3, R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3 is NH2, or CH2NH2; and X is O, OCH2, OCH2CH2, OCH(CH3), CH2O, SCH2, CH2S, CH2, NHCH2, CH2NH, N(CH3)CH2, CH2CH2, C?C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: October 17, 2023
    Assignee: Eli Lilly and Company
    Inventors: Adel Ahmed Rashad Ahmed, Joshua Ryan Clayton, Jose Eduardo Lopez, William Thomas McMillen, Ryan Edward Stites, Takako Wilson, Jacqueline Mary Wurst
  • Publication number: 20230227493
    Abstract: The present invention provides a compound of Formula I: wherein R1 is H, halogen, C1-C3 alkyl, or C1-C3 alkoxy; R2 is H or halogen; and X is O, OCH2, or CH2, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis, rheumatoid arthritis, and lupus nephritis.
    Type: Application
    Filed: February 28, 2023
    Publication date: July 20, 2023
    Inventors: Ryan Edward STITES, Jacqueline Mary WURST
  • Patent number: 11618767
    Abstract: The present invention provides a compound of Formula I: wherein R1 is H, halogen, C1-C3 alkyl, or C1-C3 alkoxy; R2 is H or halogen; and X is O, OCH2, or CH2, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis, rheumatoid arthritis, and lupus nephritis.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: April 4, 2023
    Assignee: Eli Lilly and Company
    Inventors: Ryan Edward Stites, Jacqueline Mary Wurst
  • Publication number: 20220324904
    Abstract: The present invention provides a compound of Formula I: wherein R is H or R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3, R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3 is NH2, or CH2NH2; and X is O, OCH2, OCH2CH2, OCH(CH3), CH2O, SCH2, CH2S, CH2, NHCH2, CH2NH, N(CH3)CH2, CH2CH2, C?C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.
    Type: Application
    Filed: March 22, 2022
    Publication date: October 13, 2022
    Inventors: Adel Ahmed Rashad AHMED, Joshua Ryan CLAYTON, Jose Eduardo LOPEZ, William Thomas McMILLEN, Ryan Edward STITES, Takako WILSON, Jacqueline Mary WURST
  • Publication number: 20220306681
    Abstract: The present invention provides a compound of Formula I: wherein R1 is H, halogen, C1-C3 alkyl, or C1-C3 alkoxy; R2 is H or halogen; and X is O, OCH2, or CH2, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis, rheumatoid arthritis, and lupus nephritis.
    Type: Application
    Filed: March 22, 2022
    Publication date: September 29, 2022
    Inventors: Ryan Edward STITES, Jacqueline Mary WURST
  • Publication number: 20220306680
    Abstract: The present invention provides a compound of Formula I: wherein R is hydrogen, —P(?O)(OH)2, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, and inflammatory bowel disease.
    Type: Application
    Filed: March 22, 2022
    Publication date: September 29, 2022
    Inventors: Donmienne Doen Mun LEUNG, Jacqueline Mary WURST, James Andrew JAMISON